

Guard Therapeutics receives Notice of Allowance from USPTO for ROSgard

Guard Therapeutics AB (publ.) today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for company's patent application 16/085,500 directed to the biological investigational drug ROSgard as product (composition of matter). A formal approval is expected shortly, and if granted the patent is valid until 2037. The Notice of Allowance further strengthens Guard Therapeutics' patent portfolio and improves market exclusivity for ROSgard in one of the company's key markets.

Guard Therapeutics' investigational drug ROSgard has been shown in several preclinical studies to protect against cell and organ damage, including acute kidney injury, by counteracting oxidative stress and supporting regenerative processes. The investigational drug is being developed to treat and prevent acute kidney injuries, initially in connection with cardiac surgery.

"We are pleased that the USPTO intends to grant a patent for our biological drug candidate ROSgard, which further strengthens the commercial potential of ROSgard. The Notice of Allowance reinforces our drug candidate's unique properties and is important part of the company's integrated patent portfolio", Tobias Agervald, CEO of Guard Therapeutics says.

For further information, please contact:

Tobias Agervald, CEO

Telephone: +46 46 286 50 30

E-mail: info@guardtherapeutics.com

About Guard Therapeutics

Guard Therapeutics' investigational drug ROSgard has been documented in several preclinical studies to protect against cell and organ damage, including acute kidney damage, by counteracting oxidative stress and supporting regenerative processes. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, tel. +46 11 32 30 732, ca@skmg.se.

This information is information that Guard Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2020-12-11 09:10 CET.

Press Release
11 December 2020 09:10:00 CET



Attachments

[Guard Therapeutics receives Notice of Allowance from USPTO for ROSgard](#)